Arian Pano - Sep 2, 2021 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
Chief Clinical Dev. Officer
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact for Arian Pano
Stock symbol
KNSA
Transactions as of
Sep 2, 2021
Transactions value $
$0
Form type
4
Date filed
9/7/2021, 05:19 PM
Previous filing
Jun 21, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Award $0 +23.3K $0.00 23.3K Sep 2, 2021 Class A Common Shares 23.3K $12.97 Direct F1
transaction KNSA Restricted Share Units Award $0 +3.89K $0.00 3.89K Sep 2, 2021 Class A Common Shares 3.89K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021.
F2 Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer.
F3 The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.